This is a working overview of fatty acid oxidation, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-07-20. Anything still debated is marked as such rather than presented as settled.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.
Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.
Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.
| Property | Value | Notes |
|---|---|---|
| Common name | Cardarine | Common internet and media name. |
| Research code | GW501516 | Also written GW-1516. |
| Drug class | PPARδ agonist | Not a selective androgen receptor modulator. |
| Development status | Discontinued | Clinical development halted after rodent cancer findings. |
| Regulatory status | Prohibited in sport | Listed by WADA; not approved as medicine. |
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
Published human data are sparse and mostly come from early-phase trials. Those studies examined short-term changes in lipids, glucose, and exercise capacity, but they were not large enough to establish efficacy or long-term safety. Some animal experiments reported increased running endurance, yet such findings do not prove a performance benefit in people. Anti-doping laboratories detect GW501516 and its metabolites in urine or blood using liquid chromatography-tandem mass spectrometry. Detection windows depend on dose, sample type, and individual metabolism. The method is sensitive enough to identify trace residues in tested samples.
Laboratory handling focuses on identity, purity, and stability. Reference standards are typically stored cold and dry, protected from light, because solutions can degrade over time. Analytical checks may use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Impurities and related substances can be separated chromatographically and compared with a known standard. Because cardarine is not an approved drug, compendial monographs are absent, and laboratories often rely on in-house methods. Reported purity varies among unregulated products and should not be assumed from a label.
There may be flocculation in some gels, which may produce an unstable gel. The rheology of some gels are easily altered by environmental factors such as temperature and humidity, resulting in stricter storage requirements. Syneresis of the gel may occur during storage, causing the gel to shrink unpredictably or even dry out. The gelators may precipitate and salt out, and some drugs may degrade in gel formulation due to the other ingredients present in the formulation. Some additives and gelators added into the formulation may cause irritation problems, such as skin irritation, dermatitis or allergic conditions. The increased water content in gels increases the chances of bacterial or fungal attack, which may contaminate the gel, making it unsuitable for use. Considering the direct route of administration, drugs must be very small in size to have an effective plasma concentration for action. The particle size and other properties of the drug may also affect its absorption through the skin barrier, resulting in an unreliable effect.
Jung's thought derived from the classical education he received at school and from early family influences, which on the maternal side were a combination of Reformed Protestant academic theology with an interest in occult phenomena. On his father's side was a dedication to academic discipline emanating from his grandfather - the physician, scientist, one-time student activist and convert from Catholicism to Swiss Reformed Protestantism, and first Basel Professor of Medicine, Karl Gustav Jung. Family lore also suggested there was at least a social connection to the German polymath, Johann Wolfgang Goethe, through the latter's niece, Lotte Kestner (known as "Lottchen") who was a frequent visitor in Jung senior's household. Jung had, through his marriage, the economic security to pursue interests in other intellectual topics of the moment. His early celebrity as a research scientist through the Word Association Test led to the start of prolific correspondence and worldwide travel. It opened academic as well as social avenues, supported by his explorations into anthropology, quantum physics, vitalism, Eastern and Western philosophy. He delved into epistemology, alchemy, astrology, and sociology, as well as literature and the arts. Jung's interest in philosophy and spiritual subjects led many to label him a mystic, although he preferred to be seen as a man of science. Jung, unlike Freud, was deeply knowledgeable about philosophical concepts and sought links between epistemology and emergent theories of psychology.
The enzyme is a cytochrome P450 protein containing heme, isolated from maize and other grasses. It requires a partner cytochrome P450 reductase for functional expression. This uses nicotinamide adenine dinucleotide phosphate. It is involved in the biosynthesis of protective and allelopathic compounds such as DIMBOA in some plants.
Sources: en.wikipedia.org
was renamed Merck Sharp & Dohme, and Schering-Plough renamed as "Merck & Co., Inc." The maneuver was an attempt to avoid a "change-of-control" in order to preserve Schering-Plough's rights to market Remicade. A settlement with Johnson & Johnson was reached in 2011, in which Merck agreed to pay $500 million. Merck Sharp & Dohme remains a subsidiary of the Merck & Co. parent. Richard Clark retired as CEO and company president in October 2011 and Kenneth Frazier became CEO. In October 2013, Merck announced it would cut 8,500 jobs in an attempt to cut $2.5 billion from its costs by 2015. Combined with 7,500 job cuts announced in 2011 and 2012, the layoffs amounted to 20% of its workforce. By 2014, research performed at Merck has led to U.S. FDA approval of 63 new molecular entities. In August 2014, Merck acquired Idenix Pharmaceuticals for $3.85 billion. In September 2014, the US Food and Drug Administration (FDA) approved Pembrolizumab (MK-3475) as a breakthrough therapy for melanoma treatment. In clinical trials, pembrolizumab provided partial tumor regression in about one quarter of patients, many of whom have not seen further progression of their disease in over 6 months of follow-up. In December 2014, the company acquired Swiss biotechnology company OncoEthix for up to $375 million. Between 2010 and 2015, the company cut around 36,450 jobs. During that time, the company sold its consumer health business to Bayer and narrowed the company's focus to immunology, vaccines, diabetes, emerging markets and medicines used in hospitals, like certain antibiotics.
=== Antibiotic stewardship === Procalcitonin guided cessation of antibiotic use reduces duration of antibiotic exposure and lowers mortality in critically ill patients in the Intensive Care Unit. In adult emergency department patients with respiratory tract illnesses, PCT-guided treatment groups had reduced antibiotic use. PCT references ranges are also used to determine the likelihood a patient has systemic infection (sepsis), thereby reducing incidence of unnecessary antibiotic use in cases where sepsis is unlikely. Although some literature differs in antibiotic cessation requirements the general consensus is stopping antibiotics when procalcitonin levels fall 80% below peak or below 0.5 μg/L at day five or later during antibiotic therapy.
Montgomery launched his major assault on the Mareth Line, Operation Pugilist, on 16 March. The Rhodesian Anti-Tank Battery, operating with the 50th (Northumbrian) Infantry Division, took part. The Allies advanced at first but the weather and terrain prevented the tanks and guns from moving forward, allowing the 15th Panzer Division to counter-attack successfully. A flanking movement by the 2nd New Zealand Division around the right of the German forces, through the Tebaga Gap, compelled an Axis withdrawal on 27 March. The Rhodesian anti-tank gunners fought their last action in Africa at Enfidaville, 50 kilometres (31 mi) south of Tunis, on 20 April. The KRRC Rhodesians meanwhile took part in a long outflanking march which brought them to El Arousse, 65 kilometres (40 mi) south-west of Tunis, the next day. British armour entered Tunis on 7 May 1943. The Axis forces in North Africa—over 220,000 Germans and Italians, including 26 generals—surrendered a week later. By time Tunis had fallen, few Rhodesians remained with the First or Eighth Armies; most were transferring to the South African 6th Armoured Division, then in Egypt, or making their way home on leave. Out of the 300 Southern Rhodesians who had joined the KRRC in Egypt, only three officers and 109 other ranks remained at the end of the Tunisian Campaign. The Rhodesian Anti-Tank Battery retraced many of the movements it had taken during the campaign as it returned to Egypt. "Left for Matruh at 0830 hours today," one Rhodesian gunner wrote. "Camped at night on the identical spot where we camped in June 1941.
Sources: en.wikipedia.org
Bleecker Banks* (1850s), mayor of Albany, New York; member of New York State Assembly and New York State Senate Galen A. Carter (1850), member of Connecticut Senate Stewart L. Woodford (1854), lieutenant governor of New York and U.S. minister to Spain Jacob Augustus Geissenhainer (1858), U.S. congressman from New Jersey George Lockhart Rives (1868), U.S. assistant secretary of state and chairman of the Columbia trustees Hamilton Fish II (1869), speaker of the New York State Assembly and U.S. congressman Thomas C. E. Ecclesine (1870), member of the New York State Assembly and the New York State Senate Seth Low (1870), mayor of New York City and president of Columbia University Oscar Solomon Straus (1871), first Jewish U.S. cabinet secretary, U.S. secretary of commerce and labor under Theodore Roosevelt, and U.S. ambassador to the Ottoman Empire, first president of the American Jewish Historical Society Robert Anderson Van Wyck (1871), first mayor of New York City to preside over all five boroughs Robert Ray Hamilton (1872), member of New York State Assembly, great-grandson of Alexander Hamilton P. Henry Dugro (1876), U.S. congressman from New York Benjamin Barker Odell Jr.* (1877), governor of New York; U.S. congressman from New York Thomas G. Patten (1879), U.S. congressman from New York Thomas F. Magner (1882), U.S. congressman from New York Thomas Ewing III (1883), 33rd commissioner of the United States Patent and Trademark Office Herbert L. Satterlee (1883), assistant secretary of the Navy 1908–1909, son-in-law of J. P.
=== Clinical Laboratory Development Program === The work of SHIELD Illinois will continue through the Clinical Laboratory Development Program powered by SHIELD Illinois ("CLDP"). Utilizing the state-of-the-art laboratory renovated by SHIELD Illinois at the University of Illinois Chicago, CLDP will address the critical shortage of qualified clinical laboratory personnel in Illinois. The goal of the program is to develop the next generation of laboratory technicians and scientists through hands-on training and work experience.
== Phthalimido-N-oxyl (PINO) == The radical derived by removal of a hydrogen atom from N-hydroxyphthalimide is called N-phthalimido-N-oxyl, acronym being PINO. It is a powerful H-atom abstracting agent. The bond dissociation energy of NHPI (i.e., PINO–H) is 88–90 kcal/mol (370–380 kJ/mol), depending on the solvent.
== Structure == In aqueous solutions, glycine exists predominantly as a zwitterion (H3N+CH2COO-), a polar molecule with both a positive and negative charge. The zwitterion form is stabilized by hydrogen bonding with solvent water molecules. Analysis of neutron diffraction data for glycine showed that it was in the zwitterionic form in the solid state and confirmed the presence of hydrogen bonds. Theoretical calculations have been used to show that zwitterions may also be present in the gas phase for some cases different from the simple carboxylic acid-to-amine transfer.
Sources: en.wikipedia.org
No. Cardarine is a PPARδ agonist, while selective androgen receptor modulators act on androgen receptors. The two classes differ in receptor target and downstream effects.
Preclinical rodent studies reported cancers, including liver and bladder tumors, at tested doses. The human relevance of those findings is uncertain, but development was discontinued. No approved human product resulted.
No. It remains an investigational compound without approved therapeutic labeling. Sports regulators prohibit its use, and health agencies have warned against consuming it.
It binds to and activates PPAR delta, a nuclear receptor that controls expression of genes related to fatty acid oxidation. This mechanism can alter energy metabolism in animal models. It is not a direct stimulant or fat-burning enzyme.